Table 3.
Weight change from diagnosis to 36 months after breast cancer diagnosis
| Characteristics | N | % | Median (range) | P value |
|---|---|---|---|---|
| Total | 4137 | 100.0 | 1.0 (−20.0, 27.0) | |
| Age at diagnosis (year) | <0.001 | |||
| <40 | 189 | 4.6 | 3.0 (−19.0, 27.0) | |
| 40–49 | 1619 | 39.1 | 2.0 (−17.0, 23.0) | |
| 50–59 | 1219 | 29.5 | 1.0 (−16.0, 19.0) | |
| ≥60 | 1110 | 26.8 | 0.0 (−20.0, 24.0) | |
| Education | <0.001 | |||
| <High school | 1952 | 47.2 | 1.0 (−20.0, 27.0) | |
| High school | 1545 | 37.4 | 1.0 (−19.0, 23.0) | |
| >High school | 640 | 15.5 | 1.0 (−15.0, 24.0) | |
| Income (yuan/month/capita) | 0.003 | |||
| <1000 | 2373 | 57.4 | 1.0 (−20.0, 27.0) | |
| 1000–1999 | 1284 | 31.0 | 1.0 (−19.0, 18.0) | |
| ≥2000 | 480 | 11.6 | 1.0 (−15.0, 24.0) | |
| Marital status | 0.166 | |||
| Married | 3624 | 87.6 | 1.0 (−19.0, 27.0) | |
| Other | 513 | 12.4 | 1.0 (−20.0, 21.0) | |
| Menopausal status* | <0.001 | |||
| Pre-menopausal | 837 | 20.2 | 2.0 (−19.0, 27.0) | |
| Post-menopausal | 3300 | 79.8 | 1.0 (−20.0, 24.0) | |
| Menopausal symptoms* | <0.001 | |||
| No | 1040 | 25.1 | 1.0 (−20.0, 27.0) | |
| Yes | 3097 | 74.9 | 1.0 (−19.0, 24.0) | |
| Charlson comorbidity index* | <0.001 | |||
| 0 | 3336 | 80.6 | 1.5 (−19.0, 27.0) | |
| 1 | 309 | 7.5 | 0.0 (−20.0, 21.0) | |
| ≥2 | 492 | 11.9 | −1.0 (−18.0, 12.0) | |
| Relapse/metastasis* | 0.599** | |||
| No | 3851 | 93.1 | 1.0 (−20.0, 27.0) | |
| Yes | 160 | 3.9 | 1.0 (−19.0, 19.0) | |
| Unknown | 126 | 3.0 | 1.0 (−15.0, 16.0) | |
| Chemotherapy | <0.001 | |||
| Yes | 3764 | 91.0 | 1.0 (−20.0, 27.0) | |
| No | 373 | 9.0 | 0.0 (−18.0, 24.0) | |
| Radiotherapy | <0.001 | |||
| Yes | 1262 | 30.5 | 2.0 (−19.0, 22.0) | |
| No | 2875 | 69.5 | 1.0 (−20.0, 27.0) | |
| Immunotherapy | 0.816** | |||
| Yes | 609 | 14.7 | 1.0 (−15.0, 18.0) | |
| No | 3518 | 85.0 | 1.0 (−20.0, 27.0) | |
| Unknown | 10 | 0.2 | 2.5 (−7.0, 8.0) | |
| Tamoxifen use* | 0.827 | |||
| Yes | 2706 | 67.1 | 1.0 (−19.0, 27.0) | |
| No | 1325 | 32.9 | 1.0 (−20.0, 20.0) | |
| ER/PR status | 0.281** | |||
| ER/PR positive | 2149 | 52.0 | 1.0 (−19.0, 27.0) | |
| ER/PR negative | 1082 | 26.2 | 1.0 (−20.0, 21.0) | |
| ER/PR mixed | 839 | 20.3 | 1.0 (−17.0, 22.0) | |
| ER/PR unknown | 67 | 1.6 | 1.0 (−17.0, 16.0) | |
| TNM stage | 0.009** | |||
| 0-I | 1587 | 38.4 | 1.0 (−18.0, 24.0) | |
| IIA | 1379 | 33.3 | 1.0 (−20.0, 23.0) | |
| IIB | 661 | 16.0 | 1.0 (−16.0, 20.0) | |
| III | 323 | 7.8 | 2.0 (−19.0, 27.0) | |
| Unknown | 187 | 4.5 | 2.0 (−19.0, 13.0) | |
| BMI at diagnosisξ | <0.001 | |||
| Underweight (BMK<18.5) | 163 | 3.9 | 3.0 (−4.0, 19.0) | |
| Normal (BMI: 18.5–23.9) | 2209 | 53.4 | 2.0 (−13.0, 27.0) | |
| Overweight (BMI: 24.0–27.9) | 1289 | 31.2 | 0.0 (−19.0, 23.0) | |
| Obese (BMI≥28) | 476 | 11.5 | −1.0 (−20.0, 20.0) |
*
Based on information from the 18 months post-diagnosis interview.
**
`Unknown' group was excluded from P value test
ξ
Based on Chinese criteria for overweight and obesity (ref 21)